Table 4

Characteristics of subjects who responded to the intervention with resolution of NAFLD (converters) and subjects who still had NAFLD at follow-up (non-converters)

ParameterConvertersNon-converters
BaselineFollow-upp ValueBaselineFollow-upp Valuep* Value
Gender (male/female)14/614/160.10
Age (years)45.9 (2.4)46.9 (2.4)<0.000148.4 (1.8)49.1 (1.8)<0.00010.40
Body mass index (kg/m2)30.0 (0.7)28.4 (0.7)<0.000132.5 (0.7)31.8 (0.7)0.0010.03
Waist circumference (cm)102.2 (2.3)96.3 (2.2)<0.0001106.2 (1.5)103.3 (1.5)0.0010.04
Total body fat† (kg)24.6 (1.6)20.2 (1.7)<0.000131.0 (1.9)29.8 (1.9)0.010.06
Subcutaneous abdominal fat† (kg)10.2 (0.7)9.0 (0.7)0.000513.4 (0.9)12.9 (0.8)0.040.049
Visceral adipose tissue† (kg)4.01 (0.38)3.09 (0.40)<0.00014.48 (0.27)4.18 (0.30)0.00050.02
Liver fat‡ (%)9.95 (1.02)3.68 (0.27)<0.000114.95 (1.11)11.53 (0.83)0.0020.003
AST (U/l)28.13 (3.43)23.00 (1.34)0.0928.61 (1.72)28.00 (2.68)0.160.40
ALT (U/l)36.75 (4.53)23.89 (2.55)0.00229.14 (3.35)28.48 (4.66)0.470.34
Fasting glucose (mmol/l)5.44 (0.11)5.21 (0.11)0.0065.40 (0.10)5.37 (0.12)0.290.83
2 h glucose (mmol/l)7.35 (0.35)6.11 (0.34)0.0027.88 (0.30)7.27 (0.32)0.040.73
Fasting insulin (pmol/l)74.7 (8.6)53.2 (7.7)0.00282.6 (7.1)80.4 (8.1)0.270.78
2 h insulin (pmol/l)597.0 (87.9)318.4 (80.9)<0.0001826.2 (94.4)686.0 (116.9)0.0450.69
HPA score7.88 (0.25)8.54 (0.24)0.0037.93 (0.24)8.39 (0.19)0.040.68
VO2,max (ml/min/kg)26.03 (1.34)28.85 (1.65)0.0220.61 (1.01)22.35 (1.12)0.0060.08
  • Results for follow-up and baseline are given as the mean (SE).

  • p for differences between basal and follow-up, by the matched pairs t test, except for gender (χ2 test).

  • p* for differences in parameters at baseline between converters and non-converters. Body fat compartments were adjusted for gender and age; the other parameters were additionally adjusted for total body fat. †Measured by magnetic resonance tomography. ‡Measured by magnetic resonance spectroscopy.

  • ALT, alanine aminotransferase; AST, aspartate transaminase; HPA, habitual physical activity; NAFLD, non-alcoholic fatty liver disease.